2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Refractory Anemia With Excess Blasts: new trials by email Literature Review of Refractory Anemia With Excess Blasts trials Research Report on Refractory Anemia With Excess Blasts
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC) - Myelodysplastic Syndrome, MDS | Phase 3 | Terminated | Traws Pharma, Inc. | 372 | 2015-12-02 | 2022-09-26 |
| Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine rigosertib sodium - Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts | Phase 3 | Completed | Traws Pharma, Inc. | 67 | 2013-08-01 | 2020-06-30 |
| Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome asparaginase, daunorubicin hydrochloride, fludarabine phosphate - Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7) | Phase 3 | Completed | National Cancer Institute (NCI) | 880 | 1996-08-01 | 2013-01-16 |
Anemia, Refractory, with Excess of Blasts (3) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory (1) · Cytopenia (1)
Anemia (3) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Anemia, Refractory (2) · Chronic Disease (2) · Disease Attributes (2) · Leukemia (2) · Leukemia, Myeloid (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Myelodysplastic Syndromes (1)
ON 01910 (2) · Asparaginase (1) · Busulfan (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1) · Dexamethasone (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Hydrocortisone (1) · Idarubicin (1) · Interleukin-2 (1) · Methotrexate (1)
Traws Pharma, Inc. (2) · National Cancer Institute (NCI) (1)
United States (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · Sweden (2) · Austria (1) · Belgium (1) · Canada (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · Hungary (1)
Steven M. Fruchtman, MD (2) · Beverly Lange (1)
PMID 19304957, PMID 20056794, PMID 20413658, PMID 36815378, PMID 38295280, PMID 42085603
2015 (1), U10CA098543 (1)